New products key to Schering growth
pharmafile | June 29, 2005 | News story | Sales and Marketing |Â Â Â
Schering has reiterated its goal of achieving an 18% operating margin in 2006 and is predicting further growth in the future.
The company's forecast is based on growth in its gynaecology and andrology portfolio and new treatments in oncology.
Dr Hubertus Erlen, chairman of the executive board at Schering, said the company's solid business platform and cost-saving moves would allow it to improve profitability beyond 2006.
Schering's gynaecology and andrology portfolio recorded total sales of nearly E1.8 billion in 2004, driven by revenues from its top-selling birth control pill Yasmin.
The German company is striving for global leadership in the female healthcare field, and is predicting growth in the area through the launch of two new products, oral contraceptive YAZTM, and hormone therapy treatment, Angeliq.
Both treatments have been filed with the FDA with a decision expected by the end of the year.
In its oncology portfolio, Schering has two promising treatments, oral targeted therapy PTK/ZK and non-amino bisphosphonate Bonefos.
PTK/ZK has shown positive results combined with chemotherapy for metastatic colorectal cancer and its potential is being explored in multiple solid tumour forms.
Bonefos is being investigated for the treatment of post-surgical breast cancer with results from a major trial expected in 2008.
Related articles:
Schering pins hopes on new hormone therapy products
Thursday , September 09, 2004






